Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
As healthcare costs continue to rise, accurate cost-effectiveness estimates are crucial. However, estimating the costs and outcomes of different interventions is complicated by uncertainty.
In model-based health economic evaluations (HEEs), uncertainty can arise from limited data, methodological limitations, and variability in clinical outcomes.
A recent review identified 80 methods for identifying, analyzing, and communicating uncertainty in HEEs. Quantifying uncertainty wherever possible is crucial to ensure accurate and unbiased cost-effectiveness estimates, ultimately leading to optimal allocation of healthcare resources
Recent Posts
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery
The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth
What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks
Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...